The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Bone Neoplasms

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Bone Neoplasms


High impact information on Bone Neoplasms

  • These results demonstrate that excessive tumor-induced bone destruction is involved in the generation of bone cancer pain and that osteoprotegerin may provide an effective treatment for this common human condition [5].
  • Analysis of lifetime studies of 243 beagles with skeletal burdens of radium-226 shows that the distribution of bone cancers clusters about a linear function of the logarithms of radiation dose rate to the skeleton and time from exposure until death [6].
  • Primary bone neoplasms in beagle dogs exposed by inhalation to aerosols of plutonium-238 dioxide [7].
  • Administration of a blocking antibody to NGF produced a significant reduction in both early and late stage bone cancer pain-related behaviors that was greater than or equivalent to that achieved with acute administration of 10 or 30 mg/kg of morphine sulfate [8].
  • Herpes vector-mediated expression of proenkephalin reduces bone cancer pain [9].

Chemical compound and disease context of Bone Neoplasms


Biological context of Bone Neoplasms


Anatomical context of Bone Neoplasms

  • These findings demonstrate that NCD-transduced osteoclasts can promote killing of cancer cells and introduce the exciting possibility for developing osteoclast-mediated, CD-based treatment of primary bone cancers and breast cancer metastases to bone [16].
  • To define products that are released from tumors that are involved in the generation and maintenance of bone cancer pain, we focus here on endothelin-1 (ET-1) and endothelin receptors as several tumors including human prostate and breast have been shown to express high levels of ETs and the application of ETs to peripheral nerves can induce pain [17].
  • To determine whether ATP and P2X3 receptors contribute to bone-cancer pain in a mouse model, immunohistochemical techniques were used to identify whether changes in the labeling of P2X3 receptors on epidermal nerve fibers (ENFs) occurred during tumor development [18].

Gene context of Bone Neoplasms

  • In this study, we performed expression profiling of all six human IGFBP genes in prostate and bone cancer cells and demonstrated that IGFBP1, 3 and 5 are primary 1alpha,25(OH)2D3 target genes [19].
  • Endothelin and the tumorigenic component of bone cancer pain [17].
  • Acute (10 mg/kg, i.p.) or chronic (10 mg/kg/day, p.o.) administration of the ETAR selective antagonist ABT-627 significantly attenuated ongoing and movement-evoked bone cancer pain and chronic administration of ABT-627 reduced several neurochemical indices of peripheral and central sensitization without influencing tumor growth or bone destruction [17].
  • This review examines the current evidence indicating that OPG increases bone mass, and discusses other possible beneficial effects of OPG, such as inhibition of tumour growth and relief from bone cancer pain [20].
  • Analysis of polymorphisms of the vitamin D receptor, estrogen receptor, and collagen Ialpha1 genes and their relationship with height in children with bone cancer [21].

Analytical, diagnostic and therapeutic context of Bone Neoplasms

  • Acute administration of a selective COX-2 inhibitor attenuated both ongoing and movement-evoked bone cancer pain, whereas chronic inhibition of COX-2 significantly reduced ongoing and movement-evoked pain behaviors, and reduced tumor burden, osteoclastogenesis, and bone destruction by >50% [1].
  • Trisacryl gelatin microspheres versus polyvinyl alcohol particles in the preoperative embolization of bone neoplasms [15].
  • Two new radiopharmaceuticals, 186Re-1-hydroxyethylidenediphosphonate (186Re-HEDP) and 153Sm-ethylenediaminetetramethylenephosphonate (153Sm-EDTMP), have been proposed as palliative treatments for metastatic bone cancer [22].


  1. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Sabino, M.A., Ghilardi, J.R., Jongen, J.L., Keyser, C.P., Luger, N.M., Mach, D.B., Peters, C.M., Rogers, S.D., Schwei, M.J., de Felipe, C., Mantyh, P.W. Cancer Res. (2002) [Pubmed]
  2. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Ibrahim, A., Scher, N., Williams, G., Sridhara, R., Li, N., Chen, G., Leighton, J., Booth, B., Gobburu, J.V., Rahman, A., Hsieh, Y., Wood, R., Vause, D., Pazdur, R. Clin. Cancer Res. (2003) [Pubmed]
  3. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. McGary, E.C., Weber, K., Mills, L., Doucet, M., Lewis, V., Lev, D.C., Fidler, I.J., Bar-Eli, M. Clin. Cancer Res. (2002) [Pubmed]
  4. Changes in plasma bone GLA protein during treatment of bone disease. Deftos, L.J., Parthemore, J.G., Price, P.A. Calcif. Tissue Int. (1982) [Pubmed]
  5. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Honore, P., Luger, N.M., Sabino, M.A., Schwei, M.J., Rogers, S.D., Mach, D.B., O'keefe, P.F., Ramnaraine, M.L., Clohisy, D.R., Mantyh, P.W. Nat. Med. (2000) [Pubmed]
  6. Bone cancer from radium: canine dose response explains data for mice and humans. Raabe, O.G., Book, S.A., Parks, N.J. Science (1980) [Pubmed]
  7. Primary bone neoplasms in beagle dogs exposed by inhalation to aerosols of plutonium-238 dioxide. Hahn, F.F., Mewhinney, J.A., Merickel, B.S., Guilmette, R.A., Boecker, B.B., McClellan, R.O. J. Natl. Cancer Inst. (1981) [Pubmed]
  8. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Halvorson, K.G., Kubota, K., Sevcik, M.A., Lindsay, T.H., Sotillo, J.E., Ghilardi, J.R., Rosol, T.J., Boustany, L., Shelton, D.L., Mantyh, P.W. Cancer Res. (2005) [Pubmed]
  9. Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Goss, J.R., Harley, C.F., Mata, M., O'Malley, M.E., Goins, W.F., Hu, X., Glorioso, J.C., Fink, D.J. Ann. Neurol. (2002) [Pubmed]
  10. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. Serafini, A.N., Houston, S.J., Resche, I., Quick, D.P., Grund, F.M., Ell, P.J., Bertrand, A., Ahmann, F.R., Orihuela, E., Reid, R.H., Lerski, R.A., Collier, B.D., McKillop, J.H., Purnell, G.L., Pecking, A.P., Thomas, F.D., Harrison, K.A. J. Clin. Oncol. (1998) [Pubmed]
  11. Incidence of plutonium-induced bone cancer in neutered mice. Taylor, G.N., Gardner, P., Mays, C.W., Wrenn, M.E., Charrier, K. Cancer Res. (1981) [Pubmed]
  12. Drug and hormone effects on calcium release from bone. Martin, T.J. Pharmacol. Ther. (1983) [Pubmed]
  13. Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat. Fox, A., Medhurst, S., Courade, J.P., Glatt, M., Dawson, J., Urban, L., Bevan, S., Gonzalez, I. Pain (2004) [Pubmed]
  14. Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Sevcik, M.A., Luger, N.M., Mach, D.B., Sabino, M.A., Peters, C.M., Ghilardi, J.R., Schwei, M.J., Röhrich, H., De Felipe, C., Kuskowski, M.A., Mantyh, P.W. Pain (2004) [Pubmed]
  15. Trisacryl gelatin microspheres versus polyvinyl alcohol particles in the preoperative embolization of bone neoplasms. Basile, A., Rand, T., Lomoschitz, F., Toma, C., Lupattelli, T., Kettenbach, J., Lammer, J. Cardiovascular and interventional radiology. (2004) [Pubmed]
  16. Osteoclasts direct bystander killing of cancer cells in vitro. Ramnaraine, M., Pan, W., Clohisy, D.R. Bone (2006) [Pubmed]
  17. Endothelin and the tumorigenic component of bone cancer pain. Peters, C.M., Lindsay, T.H., Pomonis, J.D., Luger, N.M., Ghilardi, J.R., Sevcik, M.A., Mantyh, P.W. Neuroscience (2004) [Pubmed]
  18. Re-organization of P2X3 receptor localization on epidermal nerve fibers in a murine model of cancer pain. Gilchrist, L.S., Cain, D.M., Harding-Rose, C., Kov, A.N., Wendelschafer-Crabb, G., Kennedy, W.R., Simone, D.A. Brain Res. (2005) [Pubmed]
  19. Regulation of multiple insulin-like growth factor binding protein genes by 1alpha,25-dihydroxyvitamin D3. Matilainen, M., Malinen, M., Saavalainen, K., Carlberg, C. Nucleic Acids Res. (2005) [Pubmed]
  20. Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. Buckley, K.A., Fraser, W.D. Ann. Clin. Biochem. (2002) [Pubmed]
  21. Analysis of polymorphisms of the vitamin D receptor, estrogen receptor, and collagen Ialpha1 genes and their relationship with height in children with bone cancer. Ruza, E., Sotillo, E., Sierrasesúmaga, L., Azcona, C., Patiño-García, A. J. Pediatr. Hematol. Oncol. (2003) [Pubmed]
  22. 153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals. Ketring, A.R. International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology. (1987) [Pubmed]
WikiGenes - Universities